{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:12:07Z","timestamp":1790741527539,"version":"4.1.0"},"reference-count":77,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,10,5]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), an inhibitor of MMP9, in combination with nivolumab (NIVO), for the treatment of advanced gastric cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Phase 2, open-label, randomized multicenter study evaluating the efficacy, safety, and pharmacodynamics of ADX+NIVO versus NIVO in patients with pretreated metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events (AEs). We explored the correlation of efficacy outcomes with biomarkers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>144 patients were randomized; 141 were treated: 81% white, 69% male, median age was 61 years in the ADX+NIVO group and 62 years in the NIVO-alone group. The ORR was 10% (95% CI 4 to 19) in the ADX+NIVO group and 7% (95% CI 2 to 16) in the NIVO-alone group (OR: 1.5 (95% CI 0.4 to 6.1; p=0.8)). There was no response or survival benefit associated with adding ADX. AE rates were comparable in both treatment groups; the most common AEs were fatigue, decreased appetite, nausea, and vomiting. Programmed cell death ligand 1, interferon-\u03b3 (IFN), and intratumoral CD8+ cell density were not associated with treatment response or survival. The gene signature most correlated with shorter survival was the epithelial-to-mesenchymal gene signature; high transforming growth factor (TGF)-\u03b2 fibrosis score was negatively associated with OS (p=0.036). Gene expression analysis of baseline tumors comparing long-(1+ years) and short-term (&lt;1\u2009year) survivors showed that GRB7 was associated with survival beyond 1\u2009year. Human epidermal growth factor receptor 2 (HER2)-positive disease was associated with significantly longer survival (p=0.0077). Median tumor mutation burden (TMB) was 2.01; patients with TMB \u2265median had longer survival (p=0.0025) and improved PFS (p=0.016). Based on a model accounting for TMB, TGF-\u03b2 fibrosis, and HER2, TMB was the main driver of survival in this patient population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Combination of ADX+NIVO had a favorable safety profile but did not improve efficacy compared with NIVO alone in patients with pretreated metastatic gastric or GEJ adenocarcinoma. HER2 positivity, higher TMB or GRB7, and lower TGF-\u03b2 were associated with improved outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02864381\">NCT02864381<\/jats:ext-link> or GS-US-296\u2013-2013.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003580","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T11:32:44Z","timestamp":1639135964000},"page":"e003580","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02864381","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-9655","authenticated-orcid":false,"given":"Manish A","family":"Shah","sequence":"first","affiliation":[{"name":"Medicine, Weill Cornell Medicine, New York, New York, USA"},{"name":"Medicine, NewYork-Presbyterian Hospital\/Weill Cornell Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton and London Hospital, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Metges","sequence":"additional","affiliation":[{"name":"Observatoire d\u00e9di\u00e9 au Cancer BPL, Brest University Hospital, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[{"name":"Division Head of Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev","family":"Wainberg","sequence":"additional","affiliation":[{"name":"Gastrointestinal Medical Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emon","family":"Elboudwarej","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wen","family":"Lin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Turner","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zavodovskaya","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Inzunza","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Patterson","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung","family":"Thai","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie Baker","family":"Brachmann","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V T","family":"Cantenacci","sequence":"additional","affiliation":[{"name":"Biological Sciences Division, University of Chicago Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"2025100312211308000_9.12.e003580.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70549-7"},{"key":"2025100312211308000_9.12.e003580.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.4585"},{"key":"2025100312211308000_9.12.e003580.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5"},{"key":"2025100312211308000_9.12.e003580.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70420-6"},{"key":"2025100312211308000_9.12.e003580.5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.760579"},{"key":"2025100312211308000_9.12.e003580.6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/cancers6010240","article-title":"Gelatinase B\/MMP-9 in tumour pathogenesis and progression","volume":"6","author":"Farina","year":"2014","journal-title":"Cancers (Basel)"},{"key":"2025100312211308000_9.12.e003580.7","doi-asserted-by":"publisher","DOI":"10.1002\/ar.21071"},{"key":"2025100312211308000_9.12.e003580.8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr552"},{"key":"2025100312211308000_9.12.e003580.9","first-page":"217","article-title":"Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer","volume":"17","author":"Iniesta","year":"2007","journal-title":"Oncol Rep"},{"key":"2025100312211308000_9.12.e003580.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.06.003"},{"key":"2025100312211308000_9.12.e003580.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0081-9"},{"key":"2025100312211308000_9.12.e003580.12","doi-asserted-by":"publisher","DOI":"10.1002\/jso.22001"},{"key":"2025100312211308000_9.12.e003580.13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-609"},{"key":"2025100312211308000_9.12.e003580.14","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0335-4"},{"key":"2025100312211308000_9.12.e003580.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2469"},{"key":"2025100312211308000_9.12.e003580.16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.4","article-title":"A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1)","volume":"37","author":"Shah","year":"2019","journal-title":"JCO"},{"key":"2025100312211308000_9.12.e003580.17","doi-asserted-by":"publisher","DOI":"10.3109\/10409238.2013.770819"},{"key":"2025100312211308000_9.12.e003580.18","first-page":"127","article-title":"Matrix metalloproteinases: their biological functions and clinical implications","volume":"106","author":"Hijova","year":"2005","journal-title":"Bratisl Lek Listy"},{"key":"2025100312211308000_9.12.e003580.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2011.06.008"},{"key":"2025100312211308000_9.12.e003580.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2673"},{"key":"2025100312211308000_9.12.e003580.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.015"},{"key":"2025100312211308000_9.12.e003580.22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.033472"},{"key":"2025100312211308000_9.12.e003580.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2009.09.017"},{"key":"2025100312211308000_9.12.e003580.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.02.164"},{"key":"2025100312211308000_9.12.e003580.25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M800266200"},{"key":"2025100312211308000_9.12.e003580.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.09.098"},{"key":"2025100312211308000_9.12.e003580.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207255"},{"key":"2025100312211308000_9.12.e003580.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"2025100312211308000_9.12.e003580.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"2025100312211308000_9.12.e003580.30","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100312211308000_9.12.e003580.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00175-3"},{"key":"2025100312211308000_9.12.e003580.32","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100312211308000_9.12.e003580.33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612"},{"key":"2025100312211308000_9.12.e003580.34","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025100312211308000_9.12.e003580.35","unstructured":"Andrews S . FastQC: a quality control tool for high throughput sequence data 2010."},{"key":"2025100312211308000_9.12.e003580.36","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv566"},{"key":"2025100312211308000_9.12.e003580.37","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4197"},{"key":"2025100312211308000_9.12.e003580.38","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"2025100312211308000_9.12.e003580.39","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25"},{"key":"2025100312211308000_9.12.e003580.40","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616"},{"key":"2025100312211308000_9.12.e003580.41","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29"},{"key":"2025100312211308000_9.12.e003580.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"2025100312211308000_9.12.e003580.43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100312211308000_9.12.e003580.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"2025100312211308000_9.12.e003580.45","doi-asserted-by":"publisher","DOI":"10.1101\/056101"},{"key":"2025100312211308000_9.12.e003580.46","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404208"},{"key":"2025100312211308000_9.12.e003580.47","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"},{"key":"2025100312211308000_9.12.e003580.48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2025100312211308000_9.12.e003580.49","doi-asserted-by":"publisher","DOI":"10.1038\/nature08460"},{"key":"2025100312211308000_9.12.e003580.50","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinformatics"},{"key":"2025100312211308000_9.12.e003580.51","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp698"},{"key":"2025100312211308000_9.12.e003580.52","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2"},{"key":"2025100312211308000_9.12.e003580.53","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M211304200"},{"key":"2025100312211308000_9.12.e003580.54","doi-asserted-by":"publisher","DOI":"10.1038\/ng1861"},{"key":"2025100312211308000_9.12.e003580.55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056707"},{"key":"2025100312211308000_9.12.e003580.56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0226"},{"key":"2025100312211308000_9.12.e003580.57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.5719"},{"key":"2025100312211308000_9.12.e003580.58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13058-017-0861-2","article-title":"The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting","volume":"19","author":"Severson","year":"2017","journal-title":"Breast Cancer Res"},{"key":"2025100312211308000_9.12.e003580.59","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs177"},{"key":"2025100312211308000_9.12.e003580.60","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602621"},{"key":"2025100312211308000_9.12.e003580.61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4361"},{"key":"2025100312211308000_9.12.e003580.62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41540-017-0011-6","article-title":"Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm","volume":"3","author":"McGrail","year":"2017","journal-title":"NPJ Syst Biol Appl"},{"key":"2025100312211308000_9.12.e003580.63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1940"},{"key":"2025100312211308000_9.12.e003580.64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025100312211308000_9.12.e003580.65","doi-asserted-by":"crossref","first-page":"26356","DOI":"10.18632\/oncotarget.15465","article-title":"Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients","volume":"8","author":"Koh","year":"2017","journal-title":"Oncotarget"},{"key":"2025100312211308000_9.12.e003580.66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10120-019-00970-8","article-title":"Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric\/gastroesophageal junction cancer","volume":"23","author":"Satoh","year":"2020","journal-title":"Gastric Cancer"},{"key":"2025100312211308000_9.12.e003580.67","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.3748\/wjg.v22.i26.5879","article-title":"HER2 heterogeneity in gastric\/gastroesophageal cancers: from benchside to practice","volume":"22","author":"Grillo","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2025100312211308000_9.12.e003580.68","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30169-8"},{"key":"2025100312211308000_9.12.e003580.69","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(20)30326-0","article-title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial","volume":"21","author":"Catenacci","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100312211308000_9.12.e003580.70","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1200\/JCO.2021.39.15_suppl.4013","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G\/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study","volume":"39","author":"Janjigian","year":"2021","journal-title":"JCO"},{"key":"2025100312211308000_9.12.e003580.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.07.001"},{"key":"2025100312211308000_9.12.e003580.72","doi-asserted-by":"publisher","DOI":"10.1126\/stke.3992007cm1"},{"key":"2025100312211308000_9.12.e003580.73","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.118"},{"key":"2025100312211308000_9.12.e003580.74","article-title":"Prognostic impact of canonical TGF-\u03b2 signaling in urothelial bladder cancer","volume":"55","author":"Stojnev","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"2025100312211308000_9.12.e003580.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8"},{"key":"2025100312211308000_9.12.e003580.76","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-1941-0","article-title":"Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing","volume":"17","author":"Cai","year":"2019","journal-title":"J Transl Med"},{"key":"2025100312211308000_9.12.e003580.77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:21:19Z","timestamp":1759519279000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":77,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/jitc-2021-003580"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003580","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}